Last quarter (Q3 2023), Verve Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Verve Therapeutics's net income was $-45.79M. See Verve Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 222.10M	$ 167.63M	$ 87.07M	$ 40.63M	$ 13.64M
Operating Income	$ -216.89M	$ -165.69M	$ -87.07M	$ -40.63M	$ -13.64M
Net Non Operating Interest Income Expense	$ 2.92M	-	$ -33.39M	$ 162.00K	$ 278.00K
Other Income Expense	$ -21.47M	$ -8.35M	$ -142.00K	$ -5.24M	$ -5.93M
Pretax Income	$ -192.50M	$ -157.33M	$ -120.31M	$ -45.70M	$ -19.30M
Tax Provision	$ 353.00K	$ 53.00K	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -192.83M	$ -157.39M	$ -120.31M	$ -45.70M	$ -19.30M
Basic EPS	$ -4.55	$ -2.91	$ -4.48	$ -2.58	$ -1.09
Diluted EPS	$ -3.09	$ -2.91	$ -4.48	$ -2.58	$ -1.09
Basic Average Shares	$ 240.98M	$ 54.02M	$ 26.87M	$ 17.74M	$ 17.74M
Diluted Average Shares	$ 240.98M	$ 54.02M	$ 26.87M	$ 17.74M	$ 17.74M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 222.10M	$ 167.63M	$ 87.07M	$ 40.63M	$ 13.64M
Net Income From Continuing And Discontinued Operation	$ -192.80M	$ -157.39M	$ -120.31M	$ -45.70M	$ -19.30M
Normalized Income	$ -78.60M	$ -124.29M	-	$ -45.70M	$ -19.30M
Interest Expense	-	-	-	-	-
EBIT	$ -194.68M	$ -157.33M	$ -86.92M	$ -40.63M	$ -13.64M
EBITDA	$ -203.00M	$ -155.56M	$ -83.88M	$ -39.30M	$ -13.54M

Currency in USD

Verve Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing